Businesswire·2025-12-09 11:30Core Insights - Compass Pathways plc is hosting a webinar on January 7, 2026, to discuss its commercial preparations for treatment-resistant depression (TRD) and clinical trial plans for post-traumatic stress disorder (PTSD) [1] - The webinar will feature discussions on patient care pathways, provider economics for multi-hour treatments, and treatment model development in TRD [2][3] - The management team will review commercial readiness activities and the emerging profile of COMP360 in TRD, highlighting the unmet need in PTSD and detailing the planned late-stage program for COMP360 in this indication [3] Company Overview - Compass Pathways is a biotechnology company focused on accelerating patient access to evidence-based innovations in mental health, particularly for those with serious mental health conditions not adequately addressed by existing treatments [5] - The company is pioneering a new treatment paradigm with its investigational COMP360 synthetic psilocybin treatment, which has received Breakthrough Therapy designation from the FDA and Innovative Licensing and Access Pathway designation in the UK for TRD [5] Webinar Details - The webinar will include perspectives from key opinion leaders (KOLs) and industry leaders on the current treatment landscape and the significant unmet needs in TRD and PTSD [3] - Speakers at the event will include notable figures in the field of psychiatry and mental wellness [7]